

Appl. No. : 10/719,547  
Filed : November 21, 2003

### AMENDMENTS TO THE CLAIMS

1. (Currently amended) A temperature-sensitive, host-range restricted mutant flavivirus, designated mutant 200, 201, wherein said virus comprises flavivirus having a phenotype in which the viral genome is modified by the introduction of a mutation, singly or in combination, taken from the group consisting of the mutations of Table 37, wherein said mutation is charge-cluster-to-alanine mutations at amino acids 2687 and 2688 of the NS5 gene, where amino acid position is given for the polyprotein of dengue virus type 4 200, 201.

2. (Original) The flavivirus of claim 1, further comprising the  $\Delta 30$  mutation.

3. (Original) The flavivirus of claim 1, wherein the flavivirus is a dengue virus type

1.

4. (Original) The flavivirus of claim 1, wherein the flavivirus is a dengue virus type

2.

5. (Original) The flavivirus of claim 1, wherein the flavivirus is a dengue virus type

3.

6. (Original) The flavivirus of claim 1, wherein the flavivirus is a dengue virus type

4.

7. (Original) The flavivirus of claim 1, wherein the flavivirus is a chimeric virus.

8. (Original) The chimeric virus of claim 7 having a dengue 1 backbone.

9. (Original) The chimeric virus of claim 7 having a dengue 2 backbone.

10. (Original) The chimeric virus of claim 7 having a dengue 3 backbone.

11. (Original) The chimeric virus of claim 7 having a dengue 4 backbone.

12. (Original) The flavivirus of claim 1, wherein the phenotype is temperature sensitivity in Vero cells or the human liver cell line HuH-7.

13. (Canceled)

14. (Canceled)

15. (Canceled)

13 ~~16~~. (Currently amended) A pharmaceutical composition comprising a pharmacologically acceptable vehicle and a flavivirus according to any of claims 1-12 +15.

17.-32. (Canceled)